FDA Enforcement Part 5: What Followed a Form 483
TL;DR
On FDA's public listing, a Form 483 led to a state board referral more often than to a Warning Letter.
FDA lists 308 Form 483s issued to compounders from 2019 through 2023. A state referral followed 77 of them. A Warning Letter followed 55, and an Untitled Letter followed 44. For 44 more, FDA closed the inspection with nothing else listed, and for 77 the listing shows nothing further.
The next step took most of a year. The median wait was about 8 months for a state referral and about 12 months for a Warning Letter.
Pick one corrective action your pharmacy finished a year ago. Can you show it is still being done today?
Why This Part Uses a Different Source
The document set behind Parts 2 through 4 cannot count what came after a Form 483, so this part counts from FDA's own listing.
That set holds the documents FDA posts as PDF files. FDA lists most Warning Letters, close-out letters, and many later letters without a PDF, so the set misses them. It holds 5 Warning Letters. FDA's listing shows 113.
FDA's page "Compounding: Inspections, Recalls, and other Actions" lists each pharmacy and outsourcing facility with its dated documents from 2019 on. I counted from that page: 399 pharmacies and outsourcing facilities, with entries through September 2026.
I also got something wrong in Part 3. I called an FMD-145 letter a hand-off letter to the state board. FDA sends it to the pharmacy, with a copy of the inspection report, once it considers the inspection closed. The state board gets a separate letter, the State Referral Letter.
What Followed a Form 483
A state referral was the most common step after a Form 483, and a Warning Letter followed about one in five.
For each Form 483 issued from 2019 through 2023, I took every document FDA lists for the same pharmacy after it, up to that pharmacy's next Form 483. The table shows the most serious one.
| Most serious step listed after the Form 483 | Form 483s | Share |
|---|---|---|
| State referral or hand-off letter | 77 | 25% |
| Warning Letter | 55 | 18% |
| Untitled Letter | 44 | 14% |
| Inspection closed, nothing else listed | 44 | 14% |
| Regulatory meeting | 11 | 4% |
| Nothing listed | 77 | 25% |
The ranking of steps is mine. FDA does not publish one. Of the 77 with nothing listed, 38 were followed by another Form 483 before any letter.
I left out Form 483s from 2024 on. Many of them are too recent for a next step to show up.
503A Pharmacies and Outsourcing Facilities Took Different Paths
State referrals went almost only to 503A pharmacies.
| Most serious step listed after the Form 483 | 503A pharmacies (211 Form 483s) | 503B outsourcing facilities (93 Form 483s) |
|---|---|---|
| State referral or hand-off letter | 73 (35%) | 2 (2%) |
| Warning Letter | 40 (19%) | 15 (16%) |
| Untitled Letter | 34 (16%) | 8 (9%) |
| Inspection closed, nothing else listed | 11 (5%) | 33 (35%) |
| Regulatory meeting | 2 (1%) | 9 (10%) |
| Nothing listed | 51 (24%) | 26 (28%) |
That matches how oversight is divided. FDA's guidance to states says state boards carry day-to-day oversight of most compounders, and outsourcing facilities register with FDA.
The State Letter Usually Arrived With the Closing Letter
For a 503A pharmacy, FDA closing its inspection and the state board getting the referral usually carried the same date.
The listing shows 192 state referral and hand-off letters. 186 went to 503A pharmacies, and 176 carry the same date as an FMD-145 letter to the pharmacy.
My reading is that FDA finished its part and passed the matter to the board. The listing does not show what any board did next.
The Next Step Took Most of a Year
The median wait from a Form 483 to the next step was 8 to 12 months.
| Step | Form 483s followed by it | Median wait |
|---|---|---|
| State referral | 97 | 8 months |
| Untitled Letter | 45 | 11 months |
| Warning Letter | 55 | 12 months |
So six months of silence after a response was normal. Most of these letters arrived later than that.
Close-Out Often Followed Another Inspection
On the listing, a Warning Letter that closed took about two years to close, and FDA usually inspected again first.
FDA says it may issue a close-out letter once the violations in a Warning Letter have been addressed, and that it may verify the correction first, including through a follow-up inspection.
The listing shows 83 Warning Letters dated 2019 through 2023. 28 of them have a later close-out letter listed, a median of about 24 months after the Warning Letter. In 18 of the 28, FDA issued a new Form 483 between the Warning Letter and the close-out.
Here is how that looked for one Arizona pharmacy. FDA lists a Warning Letter in September 2020 and a new Form 483 in October 2021. On March 16, 2022, FDA lists three documents: the Warning Letter close-out, the FMD-145 letter, and a State Referral Letter.
The other 55 Warning Letters have no close-out listed. The listing does not say why.
What Transfers to a Smaller Pharmacy
Expect a correction to be checked a year or two later, possibly by the state board.
For a 503A pharmacy on this listing, about one Form 483 in three ended with the matter referred to the state board. The wait was most of a year. Where a Warning Letter closed, FDA usually came back and inspected first.
By then, whoever is asking wants to know whether the correction is still being done. The response letter can't answer that, and the person who wrote it may have left.
What can answer it is a named owner, a schedule, a record of each time the work was done, and someone who reviews those records.
If it isn't documented, it didn't happen.
Where the Series Lands
All five parts came back to the same point. Doing the work and being able to prove it are separate, and regulators ask for both.
Part 1 found both in a single Warning Letter. Parts 2 and 3 found the same problems recurring, often at the same pharmacies. Part 4 found that FDA weighs a response mostly on evidence, scope, and whether the fix will last. This part puts a length on "last": a year or two.
The five questions from Part 1 still apply. What was expected, who owned it, when did it occur, what supports completion, and who reviewed it? Try them on one record this week.
Sources and Scope
- FDA Compounding: Inspections, Recalls, and other Actions
- FDA Field Management Directives (FMD 145: Procedure for Release of Establishment Inspection Report to the Inspected Establishment)
- FDA: About Warning and Close-Out Letters
- FDA Compounding: Information for States
- FDA Form 483 Frequently Asked Questions
Counts come from FDA's public listing as retrieved on November 10, 2026. It covers 2019 on, so a Form 483 or Warning Letter from before 2019 is not counted, and a letter that answers an older inspection can look like it has no Form 483 before it. A document is matched to the latest Form 483 listed before it for the same pharmacy, which is Pomio's method and not a link FDA states. An amended Form 483 is counted once. Four of the 308 Form 483s went to facilities the listing does not label as 503A or 503B. The listing does not contain pharmacies' responses or state board actions, and these counts do not show why any case went the way it did or what will happen in any future case. This article is educational and is not legal advice.